Colorectal carcinoma occurs in 150,000 new patients a year. Sixty percent of these patients will develop liver metastases. This application is one of four interactive applications submitted with the goal of improving long term survival for patients with colorectal carcinoma metastatic to the liver. Close collaboration will exist between this project for clinical trials and three others: (1) Dr. Fong's project using animals to characterize cellular proliferation (both normal hepatocytes and tumor cells) following liver resection and to quantitate with 124I-IUDR PET the growth of hepatic metastases; (2) Dr. Bertino's project for laboratory studies of drug resistance mechanisms, new drugs, and new gene therapies; and (3) Dr. Jhanwar's project to study genetic alterations in metastatic colorectal carcinoma. Based on the applicant's earlier work, three consecutive studies with hepatic arterial infusion (HAI) that produced median survivals of 22 to 27 months, she has the following future aims: (1) to complete a prospective randomized trial evaluating the role of HAI in the adjuvant setting; (2) to evaluate the efficacy and tolerability of HAI used in conjunction with systemic CPT-11 in two separate cohorts of patients, one of which will have undergone cryotherapy of their liver lesions (in conjunction with Dr. Fong's project, PET scans will be obtained before and after cryosurgery to document residual disease and response); and (3) to test new drugs such as AG337 (a thymidylate synthase inhibitor), new gene strategies, and other new therapies acting on leads from Dr. Bertino's laboratory findings. Hepatic tissue samples will be obtained from all patients to test prognostic factors for response and to explore resistance mechanisms and genetic alterations. Metastatic colorectal cancer is a significant health problem. Adjuvant therapy after a liver resection is a reasonable approach and understanding the kinetics of DNA synthesis and cell division in liver regeneration, using PET scanning and MR spectroscopy, may provide new insights into the optimal timing of adjuvant therapies. Cryosurgery and newer hepatic arterial therapies are therapeutic modalities that can be used in patients in whom liver resection is impossible.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
3R01CA061524-07S1
Application #
6459281
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Xie, Heng
Project Start
1993-08-01
Project End
2002-11-30
Budget Start
2000-06-01
Budget End
2002-11-30
Support Year
7
Fiscal Year
2001
Total Cost
$115,989
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Fischer, Catha; Melstrom, Laleh G; Arnaoutakis, Dean et al. (2013) Chemotherapy after portal vein embolization to protect against tumor growth during liver hypertrophy before hepatectomy. JAMA Surg 148:1103-8
Covey, Anne M; Brown, Karen T; Jarnagin, William R et al. (2008) Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg 247:451-5
Parks, Rowan; Gonen, Mithat; Kemeny, Nancy et al. (2007) Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. J Am Coll Surg 204:753-61;discussion 761-3
Schwartz, L; Brody, L; Brown, K et al. (2006) Prospective, blinded comparison of helical CT and CT arterial portography in the assessment of hepatic metastasis from colorectal carcinoma. World J Surg 30:1892-9; discussion 1900-1
Jarnagin, W R; Zager, J S; Hezel, M et al. (2006) Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy. Cancer Gene Ther 13:326-34
Akhurst, Timothy; Kates, Tara J; Mazumdar, Madhu et al. (2005) Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. J Clin Oncol 23:8713-6
Wong, Richard J; Chan, Mei-Ki; Yu, Zhenkun et al. (2004) Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12. Clin Cancer Res 10:4509-16
Stanziale, Stephen F; Stiles, Brendon M; Bhargava, Amit et al. (2004) Oncolytic herpes simplex virus-1 mutant expressing green fluorescent protein can detect and treat peritoneal cancer. Hum Gene Ther 15:609-18
Yu, Zhenkun; Eisenberg, David P; Singh, Bhuvanesh et al. (2004) Treatment of aggressive thyroid cancer with an oncolytic herpes virus. Int J Cancer 112:525-32
Wong, Richard J; Chan, Mei-Ki; Yu, Zhenkun et al. (2004) Effective intravenous therapy of murine pulmonary metastases with an oncolytic herpes virus expressing interleukin 12. Clin Cancer Res 10:251-9

Showing the most recent 10 out of 37 publications